Release Date: 29 February 2024
With 12 Approved Bispecific Antibodies The Market Sales Surpassed USD 8 Billion In 2023 Says Kuick Research In Recent Published Report
Release Date: 29 February 2024
In the ever-evolving landscape of cancer therapeutics, Roche has once again emerged as a pioneer with the late-2022 approval of Lunsumio, the third bispecific antibody in its groundbreaking portfolio, for the treatment of...
Release Date: 29 February 2024
Vabysmo, one of the flagship drugs produced by Genentech, a Roche company, has emerged as a major therapy in the field of bispecific antibodies and the pharmaceutical landscape, with extraordinary sales figures and market...
Release Date: 15 February 2024
Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights:
Release Date: 07 February 2024
Bicycle toxin conjugates are a promising advancement in targeted cancer treatment. They use bicyclic peptides to deliver toxic payloads to cancer cells. This method seeks to address the limitations of current targeted medicines, such as antibody-drug...
Release Date: 25 January 2024
The attention of stakeholders in the dynamic landscape of cancer therapy is rapidly turning to CD70-targeted treatments as a possible avenue for innovative intervention. CD70, a protein seen in many malignancies, has piqu...
Release Date: 24 January 2024
Global Cancer Antibody Combinations Market Opportunity and Clinical Trials Insight 2028 Report Findings and Highlights:
Read More
Release Date: 23 January 2024
In the relentless pursuit of effective cancer therapies, the need for novel approaches has become increasingly evident. As conventional treatments face limitations, the emergence of Delta-like ligand 3 (DLL3) as a target in the developme...
Release Date: 05 October 2023
The introduction of immunotherapies has resulted in a paradigm change in disease management in recent years. Harnessing the immune system’s power to attack diseases like cancer, has been a game changer. However, upo...
Release Date: 05 October 2023
The biopharmaceutical industry is undergoing a transformation and at its heart is the incredible development of antibody-based therapeutics. Monoclonal and bispecific antibodies have been demonstrated to be clinical and c...
Release Date: 04 October 2023
The advent of tetraspecific antibodies as the successor of monospecific and bispecific antibodies was another one of the greatest milestones achieved in the market segment of antibodies. Though tetraspecific antibodies ar...
Release Date: 04 October 2023
Through years of research to find the most effective and safe treatment interventions for treating cancer, investigators have identified several immune checkpoints over the years that are now understood to exert an inhibitory effect on the immune sys...
Release Date: 01 September 2023
China has risen to the front lines of clinical research, drugs development, and clinical trials, developing an influential global position, further molded by a number of factors contributed to its rise. The region has a m...
Release Date: 01 September 2023
China Pharmaceutical Companies Database and Drugs Pipeline Insight 2023 Highlights:
Release Date: 30 August 2023
Blincyto is a bispecific antibody developed by Amgen that was authorized in 2014 for the treatment of precursor B-cell acute lymphoblastic leukemia. The drug has since gained four additional approvals for use in various subsets of indivi...